Valuation: BioNTech SE

Market Cap 23.85B 27.86B 22.25B 20.42B 38.37B 2,665B 39.12B 264B 103B 1,336B 105B 102B 4,422B P/E 2026 *
-17.2x
P/E 2027 * -18.3x
Enterprise Value 12.48B 14.58B 11.65B 10.69B 20.08B 1,395B 20.48B 138B 53.86B 699B 54.74B 53.55B 2,314B EV / Sales 2026 *
6.91x
EV / Sales 2027 * 7.5x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.97%
1 week+20.38%
Current month+22.42%
1 month+20.32%
3 months+22.72%
6 months+0.68%
Current year+16.48%
1 week 91.01
Extreme 91.01
116
1 month 88.2
Extreme 88.2
116
Current year 79.52
Extreme 79.52
124
1 year 79.52
Extreme 79.52
124
3 years 76.53
Extreme 76.5301
131.49
5 years 76.53
Extreme 76.5301
388
10 years 12.52
Extreme 12.525
464
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 01/01/2018
Chief Executive Officer 60 02/06/2008
Director of Finance/CFO - 01/07/2025
Director TitleAgeSince
Chairman 55 02/06/2008
Director/Board Member 69 02/06/2008
Director/Board Member 65 01/01/2018
Date Insider Type Main position Quantity % Market Cap.
18/3/26 Other

Director

1,927 0.0008%
Change 5-day change 1-year change 3-year change Capi.($)
-1.97%+20.38%-0.37%+0.48% 27.86B
+2.38%+3.43%+82.88%+115.89% 73.96B
-0.23%+20.98%+53.37%+93.69% 64.66B
-4.27%-0.99%-3.38%+475.61% 27.32B
+2.74%+12.98%+62.84%+28.14% 25.97B
-0.49%+5.33%+35.64%-14.43% 19.98B
-1.79%-4.84%+239.54%+414.48% 17.84B
+0.94%+3.36%+18.55%+532.94% 16.24B
-1.29%+6.09%+41.81%+154.45% 13.3B
-2.17%+2.20%+333.02%+209.52% 12.36B
Average -0.61%+5.79%+86.39%+201.08% 29.95B
Weighted average by Cap. -0.02%+7.96%+70.35%+162.85%

Financials

2026 *2027 *
Net sales 1.81B 2.11B 1.69B 1.55B 2.91B 202B 2.96B 20B 7.8B 101B 7.92B 7.75B 335B 1.84B 2.15B 1.72B 1.58B 2.97B 206B 3.02B 20.4B 7.95B 103B 8.08B 7.91B 342B
Net income -1.35B -1.57B -1.26B -1.15B -2.17B -151B -2.21B -14.92B -5.82B -75.52B -5.91B -5.78B -250B -1.31B -1.53B -1.23B -1.12B -2.11B -147B -2.15B -14.53B -5.67B -73.55B -5.76B -5.63B -243B
Net Debt -11.37B -13.28B -10.61B -9.73B -18.29B -1,270B -18.65B -126B -49.05B -637B -49.86B -48.77B -2,108B -10.03B -11.72B -9.36B -8.59B -16.14B -1,121B -16.45B -111B -43.28B -562B -43.99B -43.03B -1,860B
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
20/08/26 USD 110.89 -1.97% 3,534,286
19/08/26 USD 113.12 +21.96% 8,780,347
18/08/26 USD 92.75 +1.26% 921,586
17/08/26 USD 91.60 -1.60% 443,531
14/08/26 USD 93.09 +1.05% 650,531
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
94.94EUR
Average target price
104.04EUR
Spread / Average Target
+9.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BNTX Stock